Search Result

Results for "

PKB

" in MCE Product Catalog:

By Targets:	Akt (9) 5-HT Receptor (5) Adenosine Receptor (1) Apoptosis (8) Autophagy (3) Casein Kinase (1) CaSR (1) CDK (1) COX (1) DNA-PK (2) EGFR (1) GHSR (1) Histamine Receptor (2) mAChR (1) Mitophagy (2) Neurokinin Receptor (3) Opioid Receptor (1) Orexin Receptor (OX Receptor) (2) P2Y Receptor (2) p38 MAPK (2) PDK-1 (1) Phosphodiesterase (PDE) (1) PI3K (2) PKA (1) Prostaglandin Receptor (1) Reactive Oxygen Species (2) TRP Channel (1) Wnt (1)
By Research Areas:	Cancer (15) Cardiovascular Disease (1) Endocrinology (3) Inflammation/Immunology (8) Metabolic Disease (2) Neurological Disease (17)

By Targets:

Akt (9)

5-HT Receptor (5)

Adenosine Receptor (1)

Apoptosis (8)

Autophagy (3)

Casein Kinase (1)

CaSR (1)

CDK (1)

COX (1)

DNA-PK (2)

EGFR (1)

GHSR (1)

Histamine Receptor (2)

mAChR (1)

Mitophagy (2)

Neurokinin Receptor (3)

Opioid Receptor (1)

Orexin Receptor (OX Receptor) (2)

P2Y Receptor (2)

p38 MAPK (2)

PDK-1 (1)

Phosphodiesterase (PDE) (1)

PI3K (2)

PKA (1)

Prostaglandin Receptor (1)

Reactive Oxygen Species (2)

TRP Channel (1)

Wnt (1)

By Research Areas:

Cancer (15)

Cardiovascular Disease (1)

Endocrinology (3)

Inflammation/Immunology (8)

Metabolic Disease (2)

Neurological Disease (17)

Inhibitors & Agonists

Peptides

Natural
Products

Recombinant Proteins

Antibodies

Targets Recommended: Akt

Cat. No.	Product Name	Target	Research Areas

HY-148868A

Akt1&PKA-IN-2	Akt CDK	Cancer
Akt1&PKA-IN-2 ((R)-29) is an inhibitor of *PKB/AKT* with cyclin-dependent kinase 2 (CDK2) selectivity. Akt1&PKA-IN-2 inhibits AKT1, PKAa and CDK2^a with IC₅₀ values of 0.007 µM, 0.01 µM and 0.69 µM, respectively.

HY-144060

AKT-IN-10	Akt	Cancer
AKT-IN-10 is a potent inhibitor of AKT. Protein kinase B (PKB, also known as AKT) is central to PI3K/AKT/mTOR signaling in cells, and its function is important for cell growth, survival, differentiation and metabolism. AKT-IN-10 has the potential for the research of breast and prostate cancer (extracted from patent WO2021185238A1, compound 4).

HY-144059

AKT-IN-9	Akt	Cancer
AKT-IN-9 is a potent inhibitor of AKT. Protein kinase B (PKB, also known as AKT) is central to PI3K/AKT/mTOR signaling in cells, and its function is important for cell growth, survival, differentiation and metabolism. AKT-IN-9 has the potential for the research of breast and prostate cancer (extracted from patent WO2021185238A1, compound 1).

HY-108657

MRS2279	P2Y Receptor	Neurological Disease
MRS2279 is a selective and high affinity P2Y1 receptor antagonist, with a K_i of 2.5 nM and an IC₅₀ of 51.6 nM. MRS2279 competitively inhibits ADP-promoted platelet aggregation with an apparent affnity (pK_B=8.05).

HY-108458

SB 452533
TRP Channel Inflammation/Immunology

SB 452533 is a potent and selective TRPV1 antagonist with the pK_b of 7.8.

SB 452533	TRP Channel	Inflammation/Immunology
SB 452533 is a potent and selective TRPV1 antagonist with the *pK_b* of 7.8.

HY-121537

CAY10404	COX Akt Apoptosis	Cancer Inflammation/Immunology Neurological Disease
CAY10404 is a potent and selective cyclooxygenase-2 (COX-2) inhibitor with an IC₅₀ of 1 nM and a selectivity index (SI; COX-1 IC₅₀/COX-2 IC₅₀) of >500000. CAY10404 is a potent *PKB/Akt* and MAPK signaling pathways inhibitor and induces apoptosis in non-small cell lung cancer (NSCLC) cells. CAY10404, a diarylisoxazole, has good analgesic, anti-inflammatory, and anti-cancer activities.

HY-139644

MIPS521	Adenosine Receptor	Neurological Disease
MIPS521 is a positive allosteric modulator of adenosine A₁ receptor (A₁AR). MIPS521 also has a lower A₁R allosteric affinity (pK_B=4.95; K_B=11 μM). MIPS521 exhibits pain-relieving effects in vivo through modulation of the increased levels of endogenous adenosine.

HY-110077

API-1	Akt Apoptosis	Cancer
API-1, a potent *Akt/PKB* inhibitor, binds to the PH domain and inhibits Akt membrane translocation. API-1 efficiently reduces the phosphorylation levels of Akt with an IC₅₀ of ∼0.8 μM. API-1 is selective for PKB and does not inhibit the activation of PKC, and PKA. API-1 also induces apoptosis by synergizing with TNF-related apoptosis-inducing ligand (TRAIL).

HY-P0141

Akt/SKG Substrate Peptide
Akt Others

Akt/SKG Substrate Peptide is a synthetic peptide suitable as a substrate for Akt/PKB, which is not phosphorylated by p70S6K or MAPK1.
HY-P0141A

Akt/SKG Substrate Peptide TFA
Akt Others

Akt/SKG Substrate Peptide TFA is a synthetic peptide suitable as a substrate for Akt/PKB, which is not phosphorylated by p70S6K or MAPK1.

Akt/SKG Substrate Peptide	Akt	Others
Akt/SKG Substrate Peptide is a synthetic peptide suitable as a substrate for Akt/PKB, which is not phosphorylated by p70S6K or MAPK1.

Akt/SKG Substrate Peptide TFA	Akt	Others
Akt/SKG Substrate Peptide TFA is a synthetic peptide suitable as a substrate for Akt/PKB, which is not phosphorylated by p70S6K or MAPK1.

HY-B1621A

Cyclopentolate hydrochloride DL-Cyclopentolate hydrochloride	mAChR	Neurological Disease
Cyclopentolate (DL-Cyclopentolate) hydrochloride is an Atropine-like muscarinic receptors antagonist with a pK_B value of 7.8 (on the circular ciliary muscle). Cyclopentolate hydrochloride is an anti-muscarinic agent commonly used in the ophthalmologic practice.

HY-10895

SB-334867 SB 334867A	Orexin Receptor (OX Receptor)	Neurological Disease Endocrinology
SB-334867 (SB 334867A) is an excellent,selective and blood–brain barrier permeable orexin-1 (OX1) receptor antagonist, shows selectivity over OX2 (pK_b=7.4), 100-fold over 5-HT_2B, 5-HT_2C with pK_i values of 5.4 and 5.3, respectively. SB-334867 reduces ethanol consumption and inhibits the acquisition of morphine-induced sensitization to locomotor activity in vivo.

HY-P1277

GR 94800	Neurokinin Receptor	Neurological Disease
GR 94800 is a potent and selective NK₂ receptor peptide antagonist, with pK_B values of 9.6, 6.4 and 6.0 for NK₂, NK₁ and NK₃ receptors, respectively.

HY-P1277A

GR 94800 TFA	Neurokinin Receptor	Neurological Disease
GR 94800 TFA is a potent and selective NK₂ receptor peptide antagonist, with pK_B values of 9.6, 6.4 and 6.0 for NK₂, NK₁ and NK₃ receptors, respectively.

HY-117851

AC-265347	CaSR	Metabolic Disease Endocrinology
AC-265347 is a calcium-sensing receptor (CaSR) agonist and positive allosteric modulator (ago-PAM) with the functional affinity (pK_B) of 5.1. AC-265347 can be used for the research of hyperparathyroidism and related diseases.

HY-10895A

SB-334867 free base SB334867A free base	Orexin Receptor (OX Receptor)	Neurological Disease Endocrinology
SB-334867 free base (SB334867A free base) is an excellent, selective and blood–brain barrier permeable orexin-1 (OX1) receptor antagonist, shows selectivity over OX2 (pK_b=7.4), 100-fold over 5-HT_2B, 5-HT_2C with pK_i values of 5.4 and 5.3, respectively. SB-334867 reduces ethanol consumption and inhibits the acquisition of morphine-induced sensitization to locomotor activity in vivo.

HY-10721

PF-AKT400 AKT protein kinase inhibitor	Akt	Cancer
PF-AKT400 is a broadly selective, potent, ATP-competitive Akt inhibitor, displays 900-fold greater selectivity for PKBα (IC₅₀=0.5 nM) than PKA (IC₅₀=450 nM).

HY-19849

BGC-20-1531 free base PGN 1531 free base	Prostaglandin Receptor	Neurological Disease
BGC-20-1531 (PGN 1531) free base is a potent and selective prostanoid EP₄ receptor antagonist, with a *pK_B* of 7.6. BGC-20-1531 free base has the potential for the research of migraine headache.

HY-P3854

GR 83074	Neurokinin Receptor	Neurological Disease
GR 83074 is a potent and selective NK-2 (Neurokinin Receptor) antagonist with a *pK_B* of 8.23. GR 83074 is inactive as an NK-3 antagonist and exhibits a 340-fold NK-2/NK-1 selectivity.

HY-119751

Hematein	Casein Kinase Akt Wnt Apoptosis	Cancer
Hematein is a oxidation product of hematoxylin acted as a dye. Hematein is an allosteric casein kinase II inhibitor with an IC₅₀ of 0.74 μM. Hematein inhibits *Akt/PKB* Ser129 phosphorylation, the Wnt/TCF pathway and increases apoptosis** in lung cancer cells.

HY-108657A

MRS2279 diammonium	P2Y Receptor	Neurological Disease
MRS2279 diammonium is a selective and high affinity P2Y1 receptor antagonist, with a K_i value of 2.5 nM and an IC₅₀ value of 51.6 nM. MRS2279 diammonium competitively inhibits ADP-promoted platelet aggregation with an *pK_b* value of 8.05.

HY-13281

PIK-75 hydrochloride	DNA-PK PI3K Apoptosis	Cancer
PIK-75 hydrochloride is a reversible DNA-PK and p110α-selective inhibitor, which inhibits DNA-PK, p110α and p110γ with IC₅₀s of 2, 5.8 and 76 nM, respectively. PIK-75 hydrochloride inhibits p110α >200-fold more potently than p110β (IC₅₀=1.3 μM). PIK-75 hydrochloride induces apoptosis.

HY-107834

PIK-75	DNA-PK PI3K Apoptosis	Cancer
PIK-75 is a reversible DNA-PK and p110α-selective inhibitor, which inhibits DNA-PK, p110α and p110γ with IC₅₀s of 2, 5.8 and 76 nM, respectively. PIK-75 inhibits p110α >200-fold more potently than p110β (IC₅₀=1.3 μM). PIK-75 induces apoptosis.

HY-113906A

(αR,8aS)-GSK1614343	GHSR	Inflammation/Immunology
(αR,8aS)-GSK1614343 (compound 18a, d2) is a cyclized ghrelin antagonist with an pIC₅₀ value of 8.4. (αR,8aS)-GSK1614343 shows a competitive antagonism of hGHSR1a with a mean *pK_b* value of 8.06.

HY-120613

BMS-986187	Opioid Receptor	Neurological Disease
BMS-986187 is an δ-opioid receptor-selective positive allosteric modulator (PAM) with an EC₅₀ of 0.03 μM and a *pK_B* of 6.02 (∼1 μM). BMS-986187 has no observable PAM activity at the μ-receptor (EC₅₀=3 μM).

HY-B1106

Tetrahydroxyquinone Tetrahydroxy-1,4-benzoquinone; Tetrahydroxybenzoquinone	Reactive Oxygen Species Apoptosis	Cancer
Tetrahydroxyquinone (Tetrahydroxy-1,4-benzoquinone), a primitive anticataract agent, is a redox active benzoquinone. Tetrahydroxyquinone can take part in a redox cycle with semiquinone radicals, leading to the formation of reactive oxygen species (ROS).

HY-B1106A

Tetrahydroxyquinone monohydrate Tetrahydroxy-1,4-benzoquinone monohydrate; Tetrahydroxybenzoquinone monohydrate	Reactive Oxygen Species Apoptosis	Cancer
Tetrahydroxyquinone monohydrate (Tetrahydroxy-1,4-benzoquinone monohydrate), a primitive anticataract agent, is a redox active benzoquinone. Tetrahydroxyquinone monohydrate can take part in a redox cycle with semiquinone radicals, leading to the formation of reactive oxygen species (ROS).

HY-107563

ROS 234	Histamine Receptor	Inflammation/Immunology
ROS 234 is a potent H3 antagonist, with a *pK_B* of 9.46 for Guinea-pig ileum H₃-receptor, a pK_i of 8.90 for Rat cerebral cortex H₃-receptor, and a ED₅₀ of 19.12 mg/kg (ip) in ex vivo of Rat cerebral cortex. ROS 234 diaplays poor central access.

HY-107563A

ROS 234 dioxalate	Histamine Receptor	Inflammation/Immunology
ROS 234 dioxalate is a potent H3 antagonist, with a *pK_B* of 9.46 for Guinea-pig ileum H₃-receptor, a pK_i of 8.90 for Rat cerebral cortex H₃-receptor, and a ED₅₀ of 19.12 mg/kg (ip) in ex vivo of Rat cerebral cortex. ROS 234 dioxalate diaplays poor central access.

HY-101222

SB-203186 hydrochloride	5-HT Receptor	Neurological Disease Cardiovascular Disease
SB-203186 hydrochloride is a potent, selective and competitive 5-HT₄ antagonist. SB-203186 hydrochloride antagonizes the 5-HT₄ receptor-mediated relaxations of the carbachol-contracted rat isolated oesophagus against 5-HT with pK_B values of 10.9 (rat oesophagus), 9.5 (guinea-pig ileum), and 9.0 (human colon) respectively.

HY-121629

PS210	PDK-1	Cancer
PS210 is a potent and selective PDK1 activator with a K_d of 3 μM and targets the PIF-binding pocket of PDK1. PS210 is inactive against other protein kinases, including PDK1 downstream signaling components such as S6K, PKB/Akt or GSK3. In cells, the prodrug of PS210 (PS423) acts as a substrate-selective inhibitor of PDK1, inhibiting the phosphorylation and activation of S6K.

HY-103152

GR 113808	5-HT Receptor	Inflammation/Immunology Neurological Disease
GR 113808 is a potent and highly selective 5-HT₄ receptor antagonist (pK_b= 8.8). GR 113808 shows 300-fold selectivity over 5-HT_1A, 5-HT_1B, 5-HT_2A, 5-HT_2C and 5-HT₃ receptors.

HY-16558

Butein 2’,3,4,4’-tetrahydroxy Chalcone	EGFR Autophagy Apoptosis Phosphodiesterase (PDE)	Cancer
Butein is a cAMP-specific PDE inhibitor with an IC₅₀ of 10.4 μM for PDE4. Butein is a specific protein tyrosine kinase inhibitor with IC₅₀s of 16 and 65 μM for EGFR and p60^c-src in HepG2 cells. Butein sensitizes HeLa cells to Cisplatin through AKT and ERK/p38 MAPK pathways by targeting FoxO3a. Butein is a SIRT1 activator (STAC).

HY-103112A

SB 243213 dihydrochloride	5-HT Receptor	Neurological Disease
SB 243213 dihydrochloride is an orally active, selective and high-affinity 5-HT_2C receptor antagonist with a pK_i of 9.37 and a *pK_b* of 9.8 for human 5-HT_2C receptor. SB 243213 dihydrochloride shows greater than a 100-fold selectivity over a wide range of neurotransmitter receptors, enzymes and ion channels. SB 243213 dihydrochloride has improved anxiolytic profile and has the potential for schizophrenia and motor disorders.

HY-103112B

SB 243213	5-HT Receptor	Neurological Disease
SB 243213 is an orally active, selective and high-affinity 5-HT_2C receptor antagonist with a pK_i of 9.37 and a *pK_b* of 9.8 for human 5-HT_2C receptor. SB 243213 shows greater than a 100-fold selectivity over a wide range of neurotransmitter receptors, enzymes and ion channels. SB 243213 has improved anxiolytic profile and has the potential for schizophrenia and motor disorders.

HY-103112

SB 243213 hydrochloride	5-HT Receptor	Neurological Disease
SB 243213 hydrochloride is an orally active, selective and high-affinity 5-HT_2C receptor antagonist with a pK_i of 9.37 and a *pK_b* of 9.8 for human 5-HT_2C receptor. SB 243213 hydrochloride shows greater than a 100-fold selectivity over a wide range of neurotransmitter receptors, enzymes and ion channels. SB 243213 hydrochloride has improved anxiolytic profile and has the potential for schizophrenia and motor disorders.

HY-10256A

Adezmapimod hydrochloride SB 203580 hydrochloride; RWJ 64809 hydrochloride	p38 MAPK Autophagy Mitophagy	Inflammation/Immunology Cancer
Adezmapimod (SB 203580) hydrochloride is a selective and ATP-competitive p38 MAPK inhibitor with IC₅₀s of 50 nM and 500 nM for SAPK2a/p38 and SAPK2b/p38β2, respectively. Adezmapimod hydrochloride inhibits LCK, GSK3β and PKBα with IC₅₀s of 100-500-fold higher than that for SAPK2a/p38. Adezmapimod hydrochloride is an autophagy and mitophagy activator.

HY-10256

Adezmapimod SB 203580; RWJ 64809	p38 MAPK Autophagy Mitophagy	Inflammation/Immunology Cancer
Adezmapimod (SB 203580) is a selective and ATP-competitive p38 MAPK inhibitor with IC₅₀s of 50 nM and 500 nM for SAPK2a/p38 and SAPK2b/p38β2, respectively. Adezmapimod inhibits LCK, GSK3β and PKBα with IC₅₀s of 100-500-fold higher than that for SAPK2a/p38. Adezmapimod does not disrupt JNK activity and is an autophagy and mitophagy activator.

HY-107544

8-pCPT-2'-O-Me-cAMP-AM	PKA	Metabolic Disease
8-pCPT-2'-O-Me-cAMP-AM is a cyclic AMP analogue, selectively activates Epac-Rap signaling pathway. 8-pCPT-2'-O-Me-cAMP-AM protects renal function by activating Epac from ischemia injury. 8-pCPT-2'-O-Me-cAMP-AM also stimulates insulin secretion by interaction with PKA pathway.

Cat. No.	Product Name	Target	Research Area

HY-P0141

Akt/SKG Substrate Peptide
Akt Others

Akt/SKG Substrate Peptide is a synthetic peptide suitable as a substrate for Akt/PKB, which is not phosphorylated by p70S6K or MAPK1.
HY-P0141A

Akt/SKG Substrate Peptide TFA
Akt Others

Akt/SKG Substrate Peptide TFA is a synthetic peptide suitable as a substrate for Akt/PKB, which is not phosphorylated by p70S6K or MAPK1.

Akt/SKG Substrate Peptide	Akt	Others
Akt/SKG Substrate Peptide is a synthetic peptide suitable as a substrate for Akt/PKB, which is not phosphorylated by p70S6K or MAPK1.

Akt/SKG Substrate Peptide TFA	Akt	Others
Akt/SKG Substrate Peptide TFA is a synthetic peptide suitable as a substrate for Akt/PKB, which is not phosphorylated by p70S6K or MAPK1.